XML 273 R216.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment information - Schedule of Segment Results (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disclosure of operating segments [line items]      
Net sales € 41,081 € 37,817 [1] € 37,651 [1]
Other revenues 3,205 3,801 [1],[2] 2,910 [1],[2]
Cost of sales (13,205) (12,628) [1] (11,882) [1]
Research and development expenses (7,394) (6,507) [1] (6,501) [1]
Selling and general expenses (9,183) (8,933) [1] (8,739) [1]
Net income attributable to non-controlling interests 58 36 [1],[3] 113 [1],[3]
Biopharma (operating segment)      
Disclosure of operating segments [line items]      
Impairment of other intangible assets, net of reversals (excluding software) 415    
Biopharma (operating segment) | Research and development projects and technology platforms      
Disclosure of operating segments [line items]      
Impairment of other intangible assets, net of reversals (excluding software) 640    
Total      
Disclosure of operating segments [line items]      
Net sales 41,081 37,817 [4] 37,651 [5],[6]
Other revenues 3,205 3,801 [4] 2,910 [5],[6]
Cost of sales (13,195) (12,619) [4] (11,879) [5],[6]
Research and development expenses (7,394) (6,507) [4] (6,501) [5],[6]
Selling and general expenses (9,183) (8,933) [4] (8,739) [5],[6]
Other operating income and expenses (3,293) (2,464) [4] (709) [5],[6]
Share of profit/(loss) from investments accounted for using the equity method 136 101 [4] 76 [5],[6]
Net income attributable to non-controlling interests (14) (18) [4] (16) [5],[6]
Business operating income 11,343 11,178 [4] 12,793 [5],[6]
Biopharma (operating segment)      
Disclosure of operating segments [line items]      
Net sales 41,081 37,817 [4],[7] 37,651 [5],[6],[7]
Other revenues 2,866 3,505 [2],[4] 2,534 [2],[5],[6]
Cost of sales (12,973) (12,415) [4] (11,682) [5],[6]
Research and development expenses (7,393) (6,505) [4] (6,499) [5],[6]
Selling and general expenses (9,113) (8,854) [4] (8,536) [5],[6]
Other operating income and expenses (3,305) (2,476) [4] (764) [5],[6]
Share of profit/(loss) from investments accounted for using the equity method 136 101 [4] 76 [5],[6]
Net income attributable to non-controlling interests (14) (18) [4] (16) [5],[6]
Business operating income 11,285 11,155 [4] 12,764 [5],[6]
Other      
Disclosure of operating segments [line items]      
Net sales 0 0 [4] 0 [5],[6]
Other revenues 339 296 [4] 376 [5],[6]
Cost of sales (222) (204) [4] (197) [5],[6]
Research and development expenses (1) (2) [4] (2) [5],[6]
Selling and general expenses (70) (79) [4] (203) [5],[6]
Other operating income and expenses 12 12 [4] 55 [5],[6]
Share of profit/(loss) from investments accounted for using the equity method 0 0 [4] 0 [5],[6]
Net income attributable to non-controlling interests 0 0 [4] 0 [5],[6]
Business operating income € 58 € 23 [4] € 29 [5],[6]
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[3] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).
[4] Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[5] (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[6] (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo
transaction (€706 million net of tax).
[7] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.